journal article·2020-01-01Open access

An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles

Khadijeh Khezri, Majid Saeedi, Katayoun Morteza-Semnani, Jafar Akbari, Seyyed Sohrab Rostamkalaei

Abstract

Kojic acid (KA) as tyrosinase inhibitor shows insufficient skin penetration and several adverse events due topical administration. KA solid lipid nanoparticles (KA-SLNs) were prepared using high speed homogenisation followed by ultra-probe sonication method for improve its effectiveness.KA-SLNs was optimised by Glyceryl mono-stearate (GMS) and Cholesterol (Chol) as lipid excipients and span 60 (SP 60) and Tween 20 (Tw 20) as co-emulsifiers (particle size 156.97 ± 7.15 nm, encapsulation efficiency 59.02 ± 0.74%, drug loading 14.755 ± 1.63%, polydispersity index (PDI) of 0.388 ± 0.004 and zeta potential (ZP) of -27.67 ± 1.89 mV). Optimum formulation (KA-SLN3 dispersion) was stable at 4 and 25 °C for 3 months. Also, TEM image confirmed these results. The results of XRD, DSC and ATR-FTIR analysis indicated that KA was well encapsulated within the SLNs either in molecularly dispersed state and stabilised in amorphous form and there was no chemical interaction between drug and other ingredients. Controlled release was achieved with this formulation. KA-SLN3 dispersion have more tyrosinase inhibition potency in comparison with pure KA. Also, the results of the ex vivo and in vitro percutaneous absorption show that KA-SLN3 dispersion improved percutaneous delivery of KA as a promising and potential novel topical preparation and might open new avenues for treatment of hyperpigmentation disorders.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Acne and Rosacea Treatments and Effects · Bee Products Chemical Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences

Student Research Committee, Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Sciences

Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences

Department of Medicinal Chemistry, Faculty of Pharmacy, Mazandaran University of Medical Sciences

Department of Pharmaceutics, Faculty of Pharmacy, Islamic Azad University, Ayatollah Amoli Branch

Medicinal plant research center, Faculty of Pharmacy, Islamic Azad University, Ayatollah Amoli Branch

Funding

Research of Mazandaran University of Medical Sciences, Mazandaran, Iran

References (82)

Show source-provided references
1. 10.4103/0378-6323.17908810.4103/0378-6323.179088 ↗
2. 10.18869/acadpub.pbr.1.1.110.18869/acadpub.pbr.1.1.1 ↗
3. 10.1002/bip.2067010.1002/bip.20670 ↗
4. 10.1016/j.jaad.2017.01.03510.1016/j.jaad.2017.01.035 ↗
5. James WD, Elston D, Berger T. Andrew’s diseases of the skin e-book: clinical dermatology-expert consult-online and print. Philadelphia: Elsevier Health Sciences, 2011.
6. 10.1111/j.1600-0536.2006.01051.x10.1111/j.1600-0536.2006.01051.x ↗
7. 10.1016/j.clindermatol.2013.05.02610.1016/j.clindermatol.2013.05.026 ↗
8. 10.1046/j.1524-4725.1999.08236.x10.1046/j.1524-4725.1999.08236.x ↗
9. 10.4103/0019-5154.5760210.4103/0019-5154.57602 ↗
10. 10.1016/j.biopha.2018.12.00610.1016/j.biopha.2018.12.006 ↗
11. 10.1177/109158181038595610.1177/1091581810385956 ↗
12. 10.1111/j.1600-0536.1998.tb05843.x10.1111/j.1600-0536.1998.tb05843.x ↗
13. 10.1111/j.1600-0536.2009.01673.x10.1111/j.1600-0536.2009.01673.x ↗
14. 10.1016/j.ijpharm.2008.06.01110.1016/j.ijpharm.2008.06.011 ↗
15. 10.1517/1742524100371348610.1517/17425241003713486 ↗
16. 10.1016/j.biomaterials.2011.07.05710.1016/j.biomaterials.2011.07.057 ↗
17. 10.1016/j.biopha.2018.07.08410.1016/j.biopha.2018.07.084 ↗
18. 10.1007/s13346-012-0088-910.1007/s13346-012-0088-9 ↗
19. 10.1016/j.msec.2016.05.11910.1016/j.msec.2016.05.119 ↗
20. 10.1016/j.colsurfb.2011.10.02410.1016/j.colsurfb.2011.10.024 ↗
21. 10.2147/IJN.S5384710.2147/IJN.S53847 ↗
22. 10.1016/j.colsurfb.2015.10.04110.1016/j.colsurfb.2015.10.041 ↗
23. Liu J-J, Nazzal S, Chang T-S, et al. Preparation and characterization of cosmeceutical liposomes loaded with avobenzone and arbutin. J Cosmet Sci. 2013;64(1):9–17.
24. 10.1007/s13346-017-0398-z10.1007/s13346-017-0398-z ↗
25. 10.1016/j.ejpb.2016.04.01610.1016/j.ejpb.2016.04.016 ↗
26. 10.1016/j.colsurfb.2016.05.06410.1016/j.colsurfb.2016.05.064 ↗
27. 10.3109/03639045.2015.107502810.3109/03639045.2015.1075028 ↗
28. 10.1016/j.carbpol.2014.12.08410.1016/j.carbpol.2014.12.084 ↗
29. 10.1016/j.colsurfb.2018.11.07210.1016/j.colsurfb.2018.11.072 ↗
30. 10.1039/C6RA12841F10.1039/C6RA12841F ↗
31. 10.1007/978-3-319-26651-010.1007/978-3-319-26651-0 ↗
32. 10.1002/jps.2271110.1002/jps.22711 ↗
33. 10.1016/j.msec.2019.11018410.1016/j.msec.2019.110184 ↗
34. 10.1016/j.colsurfb.2018.03.05210.1016/j.colsurfb.2018.03.052 ↗
35. 10.20959/wjpps20179-1006110.20959/wjpps20179-10061 ↗
36. 10.1016/j.ijbiomac.2019.05.20110.1016/j.ijbiomac.2019.05.201 ↗
37. 10.1016/j.bmc.2019.04.01610.1016/j.bmc.2019.04.016 ↗
38. 10.1080/21691401.2017.130721610.1080/21691401.2017.1307216 ↗
39. 10.1016/j.bioorg.2018.10.06910.1016/j.bioorg.2018.10.069 ↗
40. 10.1007/978-3-642-19792-510.1007/978-3-642-19792-5 ↗
41. 10.1007/s11095-012-0888-010.1007/s11095-012-0888-0 ↗
42. 10.1016/j.colsurfb.2014.02.04510.1016/j.colsurfb.2014.02.045 ↗
43. 10.1016/j.colsurfb.2015.02.04610.1016/j.colsurfb.2015.02.046 ↗
44. Yadav K, et al. Proniosomal gel: a provesicular approach for transdermal drug delivery. Der Pharmacia Lettre. 2010;2(4):189–198.
45. 10.2147/IJN.S2.3.28910.2147/IJN.S2.3.289 ↗
46. 10.1016/S0939-6411(00)00087-410.1016/S0939-6411(00)00087-4 ↗
47. Shah R. Optimisation and stability assessment of solid lipid nanoparticles using particle size and zeta potential. J Phys Sci. 2014;25(1):59–74.
48. 10.1016/j.micpath.2015.11.03110.1016/j.micpath.2015.11.031 ↗
49. 10.1016/j.ejps.2012.05.01010.1016/j.ejps.2012.05.010 ↗
50. 10.1080/03639045.2017.129166610.1080/03639045.2017.1291666 ↗
51. 10.1016/j.ijpharm.2007.03.00910.1016/j.ijpharm.2007.03.009 ↗
52. 10.1208/s12249-019-1301-710.1208/s12249-019-1301-7 ↗
53. 10.1080/0265204080237990210.1080/02652040802379902 ↗
54. 10.1016/j.dit.2013.06.01110.1016/j.dit.2013.06.011 ↗
55. 10.1016/j.colsurfb.2015.07.03210.1016/j.colsurfb.2015.07.032 ↗
56. 10.1016/j.chemphyslip.2017.08.00910.1016/j.chemphyslip.2017.08.009 ↗
57. 10.9734/BJPR/2013/277010.9734/BJPR/2013/2770 ↗
58. 10.1016/S0939-6411(98)00074-510.1016/S0939-6411(98)00074-5 ↗
59. 10.1016/j.ijpharm.2006.11.00410.1016/j.ijpharm.2006.11.004 ↗
60. 10.1021/la900694k10.1021/la900694k ↗
61. 10.1016/j.lwt.2015.11.00810.1016/j.lwt.2015.11.008 ↗
62. 10.1208/pt06022410.1208/pt060224 ↗
63. 10.1016/j.ijbiomac.2015.12.07710.1016/j.ijbiomac.2015.12.077 ↗
64. 10.4155/tde.15.2310.4155/tde.15.23 ↗
65. 10.1007/s11095-015-1677-310.1007/s11095-015-1677-3 ↗
66. 10.1016/j.ijpharm.2016.05.01710.1016/j.ijpharm.2016.05.017 ↗
67. 10.1016/S0169-409X(02)00118-710.1016/S0169-409X(02)00118-7 ↗
68. Üner M. Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Die pharmazie Int J Pharm Sci. 2006;61(5):375–386.
69. 10.1016/j.jconrel.2004.01.00510.1016/j.jconrel.2004.01.005 ↗
70. 10.1002/ardp.20120002810.1002/ardp.201200028 ↗
71. 10.1021/acs.biomac.6b0135310.1021/acs.biomac.6b01353 ↗
72. 10.1080/21691401.2017.137365910.1080/21691401.2017.1373659 ↗
73. 10.1080/0020723080236124010.1080/00207230802361240 ↗
74. 10.1111/j.1600-0846.2009.00368.x10.1111/j.1600-0846.2009.00368.x ↗
75. SCCS. Basic criteria for the in vitro assessment of dermal absorption of cosmetic ingredients. Brussels: European Commission Health & Consumers, 2010.
76. 10.2147/IJN.S13190110.2147/IJN.S131901 ↗
77. 10.1093/toxsci/58.1.1510.1093/toxsci/58.1.15 ↗
78. 10.1159/00008840710.1159/000088407 ↗
79. 10.1016/j.ijpharm.2006.08.00710.1016/j.ijpharm.2006.08.007 ↗
80. 10.1016/j.jconrel.2005.09.04510.1016/j.jconrel.2005.09.045 ↗
81. 10.1016/j.ejps.2017.11.02310.1016/j.ejps.2017.11.023 ↗
82. Riddick T. Control of colloid stability. Zeta Potential. Staunton, VA: Zeta-Meter Inc, 2007. p. 198–200.